under the jurisdiction of my colleague the Minister of National Health and Welfare (Mr. Munro). Therefore, as I have said several times in this debate, I hesitate to give answers or make statements on behalf of the Food and Drug Directorate. I do not know exactly to what product the hon. member is referring. If there are pills on the market which contain nothing but dust, I am sure this can be dealt with under the existing regulations of the Food and Drug Directorate. If the hon. member would privately, outside the house, bring to my attention the particular product of which he is speaking I would be happy to bring it to the attention of the Food and Drug Directorate.

[*Translation*]

Mr. Matte: Mr. Speaker, I would like the minister to answer the question I asked earlier in the course of my statement. Is he aware of the fact that drugs are now being sold on the market the dosage of which is not the same in French and in English?

[*English*]

Mr. Basford: Mr. Speaker, I must again mention that the Food and Drug Directorate does not come under my jurisdiction. Again I am hesitant to give answers on their behalf. They do have a regulation, the precise nature of which I am not sure about, dealing with bilingual labelling of drug products. As I say, I am not sure of the precise nature of the regulation, except that I know it exists. Again, if the hon. member would like to bring this case to my attention privately outside the house I would be happy to see that my colleague the Minister of National Health and Welfare receives the information and brings it to the attention of the Food and Drug Directorate.

Mr. Rynard: Mr. Speaker, I wonder whether the minister would make inquiries so that he could provide the answer this afternoon, because this is an important point.

Mr. Basford: The Parliamentary Secretary to the Minister of National Health and Welfare is here. I will ask him to make the inquiry. He may have something to say this afternoon.

The Acting Speaker (Mr. Béchard): Is it the pleasure of the house to adopt the amendment?

Some hon. Members: Yes.

Some hon. Members: No.

[Mr. Basford.]

The Acting Speaker (Mr. Béchard): All those in favour of the amendment please say yea.

Some hon. Members: Yea.

The Acting Speaker (Mr. Béchard): All those opposed please say nay.

Some hon. Members: Nay.

The Acting Speaker (Mr. Béchard): I declare the amendment lost on division.

Amendment (Mr. Matte) negatived.

Hon. J. W. Monteith (Perth) moved:

That Bill C-102, An Act to amend the Patent Act, the Trade Marks Act and the Food and Drugs Act, be amended by deleting in Clause 3 the words "to be sufficiently different in its composition from" in lines 12 and 13 on page 7 and substituting therefor the following words: "if it is not identical in its composition to".

• (12:50 p.m.)

Mr. Gordon Ritchie (Dauphin): Mr. Speaker, the reason for this amendment is to narrow the field within which the Food and Drug Directorate will be able to say that a product made in one country and a product made in another country, both bearing the same trade mark, are the same. It is well known that here are no international trade mark agreements and that drugs with similar trade marks, although they are not numerous, can be very different in different countries. Under this bill the Food and Drug Directorate has the authority to say that a drug with such a trade mark, manufactured in any foreign country and imported into Canada, is the same as the drug manufactured in Canada if, in the opinion of the Food and Drug Directorate, the difference is not likely to result in a hazard to health.

It is well known that there are wide variations in the effects of drugs and chemicals when they are used in the human body and, indeed, if there is any variation in the chemical potency of the drug, it cannot be called safe unless elaborate tests to prove its clinical efficacy are carried out. The Food and Drug Directorate does not have the resources nor would it be economically feasible for it to carry out the elaborate tests necessary to prove that imported drugs and drugs manufactured in Canada are the same. Under the terms of the bill the Food and Drug Directorate may declare two products with the same trade mark equal if they do not think the imported drug to be sufficiently different to constitute a hazard to health. I feel that this